OCGN Gene-Agnostic Eye Therapy Could Shift Retinal Drug Development

Key Takeaways Ocugen is advancing gene-agnostic therapies targeting multiple retinal mutations with one-time treatmentsOCGN plans a 2026 BLA filing for OCU400, with phase III data expected in early 2027.Pipeline programs like OCU410ST and OCU410 target large unmet needs with broad mutation coverage.Ocugen (OCGN) is building its ocular portfolio around a modifier gene therapy idea: instead of designing a therapy for a single genetic defect, the platform is intended to work across many underlying mutations. T ...